Inj, nyposi 1 mcg
Products billed under this code include Nypozi.
Payment limit per 1 MCG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Nypozi.
Payment limit per 1 MCG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Nypozi | Cipla USA, Inc. | 69097-0429-67 | 480 | $492.48 |
| Nypozi | Cipla USA, Inc. | 69097-0429-96 | 4800 | $4,924.80 |
| Nypozi | Cipla USA, Inc. | 69097-0430-67 | 300 | $307.80 |
| Nypozi | Cipla USA, Inc. | 69097-0430-96 | 3000 | $3,078.00 |
| Nypozi | Tanvex BioPharma USA, Inc. | 72374-0101-01 | 300 | $307.80 |
| Nypozi | Tanvex BioPharma USA, Inc. | 72374-0101-10 | 3000 | $3,078.00 |
| Nypozi | Tanvex BioPharma USA, Inc. | 72374-0102-01 | 480 | $492.48 |
| Nypozi | Tanvex BioPharma USA, Inc. | 72374-0102-10 | 4800 | $4,924.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.026 | −$0.008 | 1 MCG | Inj, nyposi 1 mcg | v1, posted September 17, 2026 |
| 3Q26 | $1.034 | +$0.006 | 1 MCG | Inj, nyposi 1 mcg | v1, posted September 15, 2026 |
| 2Q26 | $1.028 | +$0.031 | 1 MCG | Inj, nyposi 1 mcg | v1, posted September 15, 2026 |
| 1Q26 | $0.997 | – | 1 MCG | Inj, nyposi 1 mcg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.